Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Link
https://link.springer.com/content/pdf/10.1007/s00262-022-03198-1.pdf
Reference37 articles.
1. Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168
2. Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA (2014) Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer 2:19
3. Fujita K, Kim YH, Kanai O, Yoshida H, Mio T, Hirai T (2019) Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. Respir Med 146:66–70
4. Langan EA, Graetz V, Allerheiligen J, Zillikens D, Rupp J, Terheyden P (2020) Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. Lancet Oncol 21:e55–e65
5. del Castillo M, Romero FA, Argüello E, Kyi C, Postow MA, Redelman-Sidi G (2016) The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 63:1490–1493
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment;Chinese Clinical Oncology;2024-06
2. Cancer immunotherapy with immune checkpoint inhibitors and infections: A particular focus on mycobacterial infections;Respiratory Investigation;2024-05
3. Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients;BMC Pulmonary Medicine;2024-04-12
4. Fever of unknown origin associated with immune checkpoint inhibitors;Frontiers in Immunology;2024-03-12
5. A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?;Journal of Thoracic Disease;2024-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3